Rapid Dose receives Indian patent for QuickStrip

Executive Summary

• Rapid Dose Therapeutics Corp. has been granted a key patent (No. IN 582202) by the Indian Patent Office for its QuickStrip nicotine bilayer oral film technology.
• The patent covers proprietary formulation and manufacturing processes for controlled nicotine delivery, supporting the company's global intellectual property strategy initiated by a WIPO PCT filing in May 2025.
• The grant strengthens the company's position for commercial discussions with a major global nicotine company and supports its expansion into the projected $38.89-billion smoke-free nicotine market by 2033.

Key Details

• Patent Details:
  • Title: "Nicotine Bilayer Oral Film and Process for Preparation Thereof"
  • Patent Number: IN 582202
  • Application Number: IN 202441055689
  • Filing Date: July 22, 2024
  • Jurisdiction: Indian Patent Office
  • Framework: Patent Cooperation Treaty (PCT)
• Strategic Context:
  • The patent is part of a broader global IP strategy that began with a WIPO PCT filing in May 2025, extending potential protection to up to 158 jurisdictions.
  • The company intends to register the patent in other jurisdictions to unlock commercial opportunities.
  • The grant positions Rapid Dose to advance commercial agreements from a position of strength, leveraging a strategic joint ownership structure with partner Aavishkar Oral Strips.
• Market Opportunity:
  • The global modern oral nicotine market was valued at ~$7.96 billion in 2024.
  • The market is projected to reach $38.89 billion by 2033, growing at a 19% compound annual growth rate (CAGR).
  • Growth drivers include demand for smoke-free alternatives, health awareness regarding combustible cigarettes, and innovation in nicotine replacement therapy.
• Commercial Developments:
  • The milestone provides further opportunity for commercial discussions with a major global nicotine company, with which Rapid Dose has been engaged for nearly three years.
  • India is highlighted as both a significant consumer market and a major global pharmaceutical manufacturing hub.

Notable Quotes

• "This patent grant is clear evidence that RDT is delivering on the strategy we communicated to investors," said Jason Lewis, senior vice-president, business development, and co-inventor. "Our May, 2025, WIPO filing was the first step in establishing broad international protection. The PCT patent issuance, in partnership with Aavishkar, is a key milestone for systematically securing key jurisdictions and strengthening our global negotiating position."